Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results
Rhea-AI Summary
Kyntra Bio (Nasdaq: KYNB) will report fourth quarter and full year 2025 financial results on Monday, March 16, 2026 after market close. Management will host a conference call and webcast the same day at 5:00 PM ET to discuss results and provide a business update.
A live Q&A follows the presentation. A replay of the webcast will be available for a limited time on Kyntra Bio’s Events & Presentations page. Phone access requires registration to receive dial-in details.
Positive
- None.
Negative
- None.
News Market Reaction – KYNB
On the day this news was published, KYNB gained 7.31%, reflecting a notable positive market reaction. Argus tracked a peak move of +7.3% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $31M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
No peers from the Pharmaceutical Preparations sector appeared in the momentum scanner, suggesting recent trading reflects company-specific positioning rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| 2026-02-23 | Clinical data update | Positive | -9.6% | Positive Phase 1b/2 data for FG-3246 combo in mCRPC patients. |
| 2026-02-17 | Investor conferences | Positive | +6.3% | Participation in Oppenheimer and Leerink healthcare investor conferences. |
Recent history shows a mixed pattern: positive clinical data was followed by a selloff, while conference participation coincided with a price gain.
Over recent weeks, Kyntra Bio reported positive Phase 1b/2 data for FG-3246 in metastatic castration-resistant prostate cancer, including a 21% composite response rate overall and 40% in patients with only one prior ARPI, yet the stock fell 9.57% the next day. Earlier, news of participation in major investor conferences led to a 6.28% gain. Today’s earnings date announcement follows this mix of clinically positive but market-volatile news.
Market Pulse Summary
The stock moved +7.3% in the session following this news. A strong positive reaction aligns with investors positioning ahead of the scheduled earnings call and business update. The stock recently traded near its 52-week low of $6.67 and below the 200-day MA of $8.05, so upbeat expectations could have amplified upside. However, prior news showed a 9.57% drop after positive clinical data, suggesting sentiment can reverse quickly if results or commentary disappoint.
AI-generated analysis. Not financial advice.
SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
Conference Call and Webcast Presentation
Kyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone, please register here, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the Events & Presentations page on Kyntra Bio’s website.
About Kyntra Bio
Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.kyntrabio.com.
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@kyntrabio.com
FAQ
When will Kyntra Bio (KYNB) announce Q4 and full year 2025 results?
How can investors join the Kyntra Bio (KYNB) earnings call on March 16, 2026?
What time is the Kyntra Bio (KYNB) conference call on March 16, 2026?
Will Kyntra Bio (KYNB) provide a replay of the March 16, 2026 webcast?
Where can I find dial-in details to access the Kyntra Bio (KYNB) earnings call by phone?
